The TNFα-binding domain of the therapeutic antibody adalimumab elicits CD4 T-cell responses in rheumatoid arthritis patients

The TNFα-binding domain of the therapeutic antibody adalimumab elicits CD4 T-cell responses in rheumatoid arthritis patients

Treatment efficacy of patients receiving anti-TNF antibodies is limited by the formation of anti-drug antibodies. These are observed in most adalimumab-treated rheumatoid arthritis patients, despite the adjuvant-free and human sequence-derived nature of the antibody. The class switched phenotype and...

Full description

Saved in:
Bibliographic Details
Main Authors: Mateusz Makuch, Josine van Beek, Carla A. Wijbrandts, Marja Aalbers, Philippe Stas, Alexander B. Meijer, Anja ten Brinke, Theo Rispens, Paul Peter Tak, Gertjan Wolbink, Janine Schuurman, Paul W. H. I. Parren, S. Marieke van Ham
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Immunology
Subjects:
anti-drug antibodies
anti-TNF therapy
immunogenicity
rheumatoid arthritis
CD4 T cells
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1549781/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1549781/full

Similar Items